Real-world evidence from the Global aHUS Registry confirms the safety and effectiveness of switching to ravulizumab from eculizumab in patients with aHUS: a plain language summary
A new study using data from the Global aHUS Registry looked at 60 patients who switched from eculizumab to ravulizumab, including 15 kidney transplant recipients. The study found that ravulizumab was safe, with only a few mild side effects, and no serious infections or deaths. Effectiveness was also confirmed: patients maintained stable kidney function, and none needed dialysis or a kidney transplant after switching.
The study provides real-world evidence that ravulizumab is safe and works in patients with aHUS after switching from eculizumab.
This plain summaryis available in English, French, German, Spanish, Japanese, and Portuguese. You can access it here: www.tandfonline.com/doi/abs/10.1080/23995270.2025.2494461
This is a summary of an article titled ‘Global aHUS Registry Analysis of Patients Switching to Ravulizumab from Eculizumab’, originallypublished in Kidney International Reports. The full article is freely available and can be read at: www.kireports.org/article/S2468-0249(24)01796-0/fulltext